

## RECENTE LETTERATURA SCIENTIFICA SUI BENEFICI E MECCANISMI D'AZIONE DELLA N-ACETILCISTEINA NEL TRATTAMENTO DELLA COVID-19 E DELLA TOSSINA PROTEINA SPIKE

2022

Kumar P, Osahon O, Vides DB, Hanania N, Minard CG, Sekhar RV. Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation. *Antioxidants (Basel)*. 2021;11(1):50. Published 2021 Dec 27. doi:10.3390/antiox11010050  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773164/>

Di Marco F, Foti G, Corsico AG. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19? *Eur Rev Med Pharmacol Sci*. 2022 Jan;26(2):715-721. doi: 10.26355/eurrev\_202201\_27898. PMID: 35113447.  
<https://www.europeanreview.org/wp/wp-content/uploads/715-721.pdf>

Perla-Kaján J, Jakubowski H. COVID-19 and One-Carbon Metabolism. *Int J Mol Sci*. 2022;23(8):4181. Published 2022 Apr 10. doi:10.3390/ijms23084181  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026976/>

Avdeev SN, Gaynitdinova VV, Merzhoeva ZM, Berikhanov ZG. N-acetylcysteine for the treatment of COVID-19 among hospitalized patients. *J Infect*. 2022;84(1):94-118. doi:10.1016/j.jinf.2021.07.003  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271031/>

Suhail S, Zajac J, Fossum C, et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. *Protein J*. 2020;39(6):644-656. doi:10.1007/s10930-020-09935-8  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587547/>

Chen B, Raja K, Pierre-Louis F, et al. Intravenous N-Acetylcysteine in Management of COVID-19: A Case Series [published online ahead of print, 2022 Mar 24]. *J Pharm Pract*. 2022;8971900221080283. doi:10.1177/08971900221080283  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958286/>

Izquierdo JL, Soriano JB, González Y, et al. Use of N-Acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. *Sci Prog*. 2022;105(1):368504221074574. doi:10.1177/00368504221074574  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795755/>

Coelho Dos Reis JGA, Ferreira GM, Lourenço AA, et al. Ex-vivo mucolytic and anti-inflammatory activity of BromAc in tracheal aspirates from COVID-19. *Biomed Pharmacother*. 2022;148:112753. doi:10.1016/j.biopha.2022.112753  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8872962/>

Goc A, Niedzwiecki A, Ivanov V, Ivanova S, Rath M. Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants. *Eur J Microbiol Immunol (Bp)*. 2022;11(4):87-94. Published 2022 Jan 21. doi:10.1556/1886.2021.00022  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830412/>

Murae M, Shimizu Y, Yamamoto Y, et al. The function of SARS-CoV-2 spike protein is impaired by disulfide-bond disruption with mutation at cysteine-488 and by thiol-reactive N-acetyl-cysteine and glutathione [published online ahead of print, 2022 Jan 29]. *Biochem Biophys Res Commun*. 2022;597:30-36. doi:10.1016/j.bbrc.2022.01.106  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800159/>

Chen G, Lu H. Oral high-dose acetylcysteine: Effective against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)? *Drug Discov Ther*. 2022 May 6. doi: 10.5582/ddt.2022.01032. Epub ahead of print. PMID: 35527020.  
<https://pubmed.ncbi.nlm.nih.gov/35527020/>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864717/>

Lizzo G, Migliavacca E, Lamers D, Frézal A, Corthesy J, Vinyes-Parès G, Bosco N, Karagounis LG, Hövelmann U, Heise T, von Eynatten M and Gut P (2022) A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage. *Front. Aging* 3:852569. doi: 10.3389/fragi.2022.852569

<https://www.frontiersin.org/articles/10.3389/fragi.2022.852569/full>

Lapenna D. Regarding: Hypoalbuminemia in COVID-19. *J Intern Med.* 2022;291(3):388-389. doi:10.1111/joim.13403  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661995/>

El Shehaby, D.M., Mohammed, M., Ebrahim, N.E. et al. The emerging therapeutic role of some pharmacological antidotes in management of COVID-19. *Egypt J Bronchol* 16, 5 (2022). <https://doi.org/10.1186/s43168-021-00105-7>

Outcomes in COVID-19 N-acetylcysteine studies  
<https://c19early.com/nameta.html>

<https://www.marketwatch.com/press-release/acetylcysteine-market-2022-scope-of-the-report-challenges-and-trends-growing-market-with-covid-19-impact-key-regions-and-key-players-analysis-by-2028-2022-03-08>

Vestibular Paroxysmia Successfully Treated with N-acetylcysteine: A Case Report (P13-12.002)  
Courtney Iser, Karissa Arca, David Dodick, Jamie Bogle  
*Neurology* May 2022, 98 (18 Supplement) 1662; [https://n.neurology.org/content/98/18\\_Supplement/1662](https://n.neurology.org/content/98/18_Supplement/1662)

## 2021

Grishin AM, Dolgova NV, Harms S, et al. Spike protein disulfide disruption as a potential treatment for SARS-CoV-2. *bioRxiv* 2021 Jan 4. (Preprint)  
(<https://doi.org/10.1101/2021.01.02.425099>)  
<https://www.biorxiv.org/content/10.1101/2021.01.02.425099v1.full.pdf>

Manček-Keber M, Hafner-Bratkovič I, Lainšček D, et al. Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs. *FASEB J.* 2021;35(6):e21651. doi:10.1096/fj.202100560R  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206760/>

Santos AF, Póvoa P, Paixão P, Mendonça A, Taborda-Barata L. Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19. *Front Chem.* 2021;9:685196. Published 2021 Sep 10. doi:10.3389/fchem.2021.685196  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461303/>

Martin BR, Richardson J. An Exploratory Review of Potential Adjunct Therapies for the Treatment of Coronavirus Infections. *J Chiropr Med.* 2021;20(4):199-217. doi:10.1016/j.jcm.2021.12.005  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664662/>

Menicagli R, Limodio M, Limodio M, Casotti MT, Menicagli L. Pulmonary Covid Fibrosis a New Pharmaceutic Approach. *Int J Prev Med.* 2021;12:35. Published 2021 Mar 29. doi:10.4103/ijpvm.IJPVM\_462\_20  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218809/>

Chavarría AP, Vázquez RRV, Cherit JGD, et al. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19. *Comput Struct Biotechnol J.* 2021;19:1379-1390. doi:10.1016/j.csbj.2021.02.009  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910139/>

Darenskaya M, Kolesnikova L, Kolesnikov S. The Association of Respiratory Viruses with Oxidative Stress and Antioxidants. Implications for the COVID-19 Pandemic. *Curr Pharm Des.* 2021;27(13):1618-1627. doi: 10.2174/1381612827666210222113351. PMID: 33618639.  
<https://pubmed.ncbi.nlm.nih.gov/33618639/>

Ribeiro TB, Mazotti TA, Silva NAO, Stein AT, Diaz-Quijano FA, Melo DO. Evaluation of the initial response in clinical trial efforts for COVID-19 in Brazil. *Rev Bras Epidemiol.* 2021 Jan 6;23:e200104. Portuguese, English. doi: 10.1590/1980-549720200104. Erratum in: *Rev Bras Epidemiol.* 2021 May 24;24:e200104ERRATUM. PMID: 33439937.  
<https://doi.org/10.1590/1980-549720200104>

Taher A, Lashgari M, Sedighi L, Rahimi-Bashar F, Poorolajal J, Mehrpooya M. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. *Pharmacol Rep.* 2021;73(6):1650-1659. doi:10.1007/s43440-021-00296-2  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8191712/>

McCarty MF, Iloki Assanga SB, Lewis Luján L, O'Keefe JH, DiNicolantonio JJ. Nutraceutical Strategies for Suppressing NLRP3 Inflammasome Activation: Pertinence to the Management of COVID-19 and Beyond. *Nutrients*. 2020;13(1):47. Published 2020 Dec 25. doi:10.3390/nu13010047 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823562/>

Rahimi A, Samimagham HR, Azad MH, Hooshyar D, Arabi M, Kazemijahromi M. The efficacy of N-Acetylcysteine in severe COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial. *Trials*. 2021;22(1):271. Published 2021 Apr 12. doi:10.1186/s13063-021-05242-4 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040363/>

Dominari A, Hathaway Iii D, Kapasi A, et al. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. *World J Virol*. 2021;10(2):34-52. doi:10.5501/wjv.v10.i2.34 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995409/>

Assimakopoulos SF, Aretha D, Komninos D, Dimitropoulou D, Lagadinou M, Leonidou L, Oikonomou I, Mouzaki A, Marangos M. N-acetyl-cysteine reduces the risk for mechanical ventilation and mortality in patients with COVID-19 pneumonia: a two-center retrospective cohort study. *Infect Dis (Lond)*. 2021 Nov;53(11):847-854. doi: 10.1080/23744235.2021.1945675. Epub 2021 Jun 29. PMID: 34182881. <https://pubmed.ncbi.nlm.nih.gov/34182881/>

Pedre B, Barayeu U, Ezeriņa D, Dick TP. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H<sub>2</sub>S and sulfane sulfur species. *Pharmacol Ther*. 2021 Dec;228:107916. doi: 10.1016/j.pharmthera.2021.107916. Epub 2021 Jun 23. PMID: 34171332. <https://doi.org/10.1016/j.pharmthera.2021.107916>

Cárdenas-Rodríguez N, Bandala C, Vanoye-Carlo A, Ignacio-Mejía I, Gómez-Manzo S, Hernández-Cruz EY, Pedraza-Chaverri J, Carmona-Aparicio L, Hernández-Ochoa B. Use of Antioxidants for the Neuro-Therapeutic Management of COVID-19. *Antioxidants (Basel)*. 2021 Jun 17;10(6):971. doi: 10.3390/antiox10060971. PMID: 34204362; PMCID: PMC8235474. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235474/>

Zhou N, Yang X, Huang A, Chen Z. The Potential Mechanism of N-acetylcysteine in Treating COVID-19. *Curr Pharm Biotechnol*. 2021;22(12):1584-1590. doi: 10.2174/1389201021999201228212043. PMID: 33371832. <https://pubmed.ncbi.nlm.nih.gov/33371832/>

de Alencar JCG, Moreira CL, Müller AD, et al. Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19). *Clin Infect Dis*. 2021;72(11):e736-e741. doi:10.1093/cid/ciaa1443 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543361/>

Wong KK, Lee SWH, Kua KP. N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence. *J Inflamm Res*. 2021;14:2993-3013. Published 2021 Jul 6. doi:10.2147/JIR.S306849 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274825/>

Mohanty RR, Padhy BM, Das S, Meher BR. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence. *Eur Rev Med Pharmacol Sci*. 2021 Mar;25(6):2802-2807. doi: 10.26355/eurrev\_202103\_25442. PMID: 33829465. <https://www.europeanreview.org/article/25442>

Lana JFSD, Lana AVSD, Rodrigues QS, Santos GS, Navani R, Navani A, da Fonseca LF, Azzini GOM, Setti T, Mosaner T, Simplicio CL, Setti TM. Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset. *Adv Redox Res*. 2021 Dec;3:100015. doi: 10.1016/j.arres.2021.100015. Epub 2021 Aug 8. PMID: 35425932; PMCID: PMC8349474. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349474/>

Qiao Q, Liu X, Yang T, et al. Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design. *Acta Pharm Sin B*. 2021;11(10):3060-3091. doi:10.1016/j.apsb.2021.04.023 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102084/>

Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL, van der Voort PHJ, van Goor H, van Hezik EJ. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019. *Antioxid Redox Signal*. 2021 Nov 10;35(14):1207-1225. doi: 10.1089/ars.2020.8247. Epub 2021 Mar 25. PMID: 33607929. <https://pubmed.ncbi.nlm.nih.gov/33607929/>

Cazzola M, Rogliani P, Salvi SS, Ora J, Matera MG. Use of Thiols in the Treatment of COVID-19: Current Evidence. *Lung*. 2021;199(4):335-343. doi:10.1007/s00408-021-00465-3 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390541/>

- Grieb P, Swiatkiewicz M, Prus K, Rejdak K. Hypoxia may be a determinative factor in COVID-19 progression. *Curr Res Pharmacol Drug Discov.* 2021;2:100030. doi:10.1016/j.crphar.2021.100030  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106824/>
- Hussain M, Khurram Syed S, Fatima M, et al. Acute Respiratory Distress Syndrome and COVID-19: A Literature Review. *J Inflamm Res.* 2021;14:7225-7242. Published 2021 Dec 21. doi:10.2147/JIR.S334043  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710428/>
- Attiq A, Yao LJ, Afzal S, Khan MA. The triumvirate of NF- $\kappa$ B, inflammation and cytokine storm in COVID-19. *Int Immunopharmacol.* 2021;101(Pt B):108255. doi:10.1016/j.intimp.2021.108255  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8516728/>
- Akhter J, Quémès G, Pillai K, et al. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2. *Viruses.* 2021;13(3):425. Published 2021 Mar 6. doi:10.3390/v13030425  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999995/>
- Rafiee B, Bagher Tabei SM. The effect of N-acetyl cysteine consumption on men with abnormal sperm parameters due to positive history of COVID-19 in the last three months. *Arch Ital Urol Androl.* 2021 Dec 21;93(4):465-467. doi: 10.4081/aiua.2021.4.465. PMID: 34933532.  
<https://www.pagepressjournals.org/index.php/aiua/article/view/aiua.2021.4.465>
- DE Flora S, Balansky R, LA Maestra S. Antioxidants and COVID-19. *J Prev Med Hyg.* 2021;62(1 Suppl 3):E34-E45. Published 2021 Jun 5. doi:10.15167/2421-4248/jpmh2021.62.1S3.1895  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452284/>
- Kontoghiorghes GJ, Fetta S, Kontoghiorghes CN. The need for a multi-level drug targeting strategy to curb the COVID-19 pandemic. *Front Biosci (Landmark Ed).* 2021 Dec 30;26(12):1723-1736. doi: 10.52586/5064. PMID: 34994185.  
<https://www.imrpess.com/journal/FBL/26/12/10.52586/5064>
- Fratta Pasini AM, Stranieri C, Cominacini L, Mozzini C. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications. *Antioxidants (Basel).* 2021;10(2):272. Published 2021 Feb 10. doi:10.3390/antiox10020272  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916604/>
- Bernard Demot, Kristin Ivan Mark Hizon, 538. The Role of N-acetylcysteine on Post Covid-19 Pulmonary Fibrosis, *Open Forum Infectious Diseases*, Volume 8, Issue Supplement\_1, November 2021, Pages S370–S371, <https://doi.org/10.1093/ofid/ofab466.737>
- Faverio P, Rebora P, Rossi E, et al. Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study. *ERJ Open Res.* 2021;8(1):00542-2021. Published 2021 Feb 7. doi:10.1183/23120541.00542-2021  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646003/>
- Wang R, Chan JF, Wang S, et al. Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy. *Chem Sci.* 2021;13(8):2238-2248. Published 2021 Dec 3. doi:10.1039/d1sc04515f
- Raghu G, Berk M, Campochiaro PA, et al. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. *Curr Neuropharmacol.* 2021;19(8):1202-1224. doi:10.2174/1570159X19666201230144109  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719286/>
- Bourgonje AR, Offringa AK, van Eijk LE, Abdulle AE, Hillebrands JL, van der Voort PHJ, van Goor H, van Hezik EJ. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019. *Antioxid Redox Signal.* 2021 Nov 10;35(14):1207-1225. doi: 10.1089/ars.2020.8247. Epub 2021 Mar 25. PMID: 33607929.  
<https://www.liebertpub.com/doi/10.1089/ars.2020.8247>

2020

- Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. *Med Hypotheses*. 2020;143:109862. doi:10.1016/j.mehy.2020.109862  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261085/>
- Shi Z, Puyo CA. N-Acetylcysteine to Combat COVID-19: An Evidence Review. *Ther Clin Risk Manag*. 2020;16:1047-1055. Published 2020 Nov 2. doi:10.2147/TCRM.S273700  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649937/>
- De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. *FASEB J*. 2020;34(10):13185-13193. doi:10.1096/fj.202001807  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436914/>
- Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. *In Vivo*. 2020;34(3 Suppl):1567-1588. doi:10.21873/invivo.11946  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378025/>
- Jorge-Aarón RM, Rosa-Ester MP. N-acetylcysteine as a potential treatment for COVID-19. *Future Microbiol*. 2020;15:959-962. doi:10.2217/fmb-2020-0074  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359418/>
- Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-19? *Cleve Clin J Med*. 2020 Jun 8. doi: 10.3949/ccjm.87a.ccc046. Epub ahead of print. PMID: 32513807.  
<https://www.ccjm.org/content/early/2020/06/08/ccjm.87a.ccc046.long>
- Luo P, Liu Y, Liu D, Li J. Perspectives for the Use of N-acetylcysteine as a Candidate Drug to Treat COVID-19. *Mini Rev Med Chem*. 2021;21(3):268-272. doi: 10.2174/1389557520666201027160833. PMID: 33109047.  
<https://pubmed.ncbi.nlm.nih.gov/33109047/>
- Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. *Clin Immunol*. 2020;219:108544. doi:10.1016/j.clim.2020.108544  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374140/>
- Wu J. Tackle the free radicals damage in COVID-19. *Nitric Oxide*. 2020;102:39-41. doi:10.1016/j.niox.2020.06.002  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837363/>
- Ferreira AO, Polonini HC, Dijkers ECF. Postulated Adjuvant Therapeutic Strategies for COVID-19. *J Pers Med*. 2020;10(3):80. Published 2020 Aug 5. doi:10.3390/jpm10030080  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565841/>
- Silvagno F, Vernone A, Pescarmona GP. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. *Antioxidants (Basel)*. 2020;9(7):624. Published 2020 Jul 16. doi:10.3390/antiox9070624  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402141/>
- Alamdari DH, Moghaddam AB, Amini S, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. *Eur J Pharmacol*. 2020;885:173494. doi:10.1016/j.ejphar.2020.173494  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440159/>
- Liu Y, Wang M, Luo G, et al. Experience of N-acetylcysteine airway management in the successful treatment of one case of critical condition with COVID-19: A case report. *Medicine (Baltimore)*. 2020;99(42):e22577. doi:10.1097/MD.00000000000022577  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571913/>
- Atefi N, Behrangi E, Mozafarpour S, Seirafianpour F, Peighambari S, Goodarzi A. N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study. *J Res Med Sci*. 2020;25:109. Published 2020 Nov 26. doi:10.4103/jrms.JRMS\_777\_20  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019127/>
- Daid SS, Toribio AD, Lakshmanan S, Satta A, Epstein A. Spontaneous Intraparenchymal Hepatic Hemorrhage as a Sequela of COVID-19. *Cureus*. 2020;12(9):e10447. Published 2020 Sep 14. doi:10.7759/cureus.10447  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7557520/>

DiNicolantonio JJ, Barroso-Aranda J. Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole. *Med Hypotheses*. 2020;143:110051. doi:10.1016/j.mehy.2020.110051 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330590/>

Guglielmetti G, Quaglia M, Sainaghi PP, et al. "War to the knife" against thromboinflammation to protect endothelial function of COVID-19 patients. *Crit Care*. 2020;24(1):365. Published 2020 Jun 19. doi:10.1186/s13054-020-03060-9 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303575/>

Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. *Pharmacotherapy*. 2020;40(11):1166-1171. doi:10.1002/phar.2464 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537093/>

Hamidi Alamdari D, Bagheri Moghaddam A, Amini S, Hamidi Alamdari A, Damsaz M, Yarahmadi A. The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol. *Arch Bone Jt Surg*. 2020;8(Suppl1):291-294. doi:10.22038/abjs.2020.47745.2349 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296601/>

Nasi A, McArdle S, Gaudernack G, et al. Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention. *Toxicol Rep*. 2020;7:768-771. Published 2020 Jun 18. doi:10.1016/j.toxrep.2020.06.003 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301821/>

Polonikov A. Endogenous Deficiency of Glutathione as the Most Likely Cause of Serious Manifestations and Death in COVID-19 Patients. *ACS Infect Dis*. 2020;6(7):1558-1562. doi:10.1021/acsinfecdis.0c00288 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263077/>